Results for the year ended 31 December 2025

AI SummaryClose X

Poolbeg Pharma plc reported its audited results for the year ended December 31, 2025, highlighting a cash balance of £7.7 million, sufficient funding through to 2027, and gross proceeds of £4.865 million raised in an oversubscribed June 2025 fundraise. The company is progressing constructive partnering discussions, anticipating strong potential from its clinical trials, with interim data from the POLB 001 TOPICAL trial expected in the summer. Significant progress was made on POLB 001, including FDA Orphan Drug Designation and European patent grants, with independent research indicating multi-billion-dollar peak sales potential in the United States. The company also reported a loss for the year of £5.7 million.

Disclaimer*

UK 100

Latest directors dealings